SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

SAGE Therapeutics Inc (NYSE:SAGE) is in the spotlight today, after the drugmaker received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential Huntington's disease treatment.

Biotech Stock Moves Higher After Fast-Track Designation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington's disease (HD). Fast Track is a process designed to facilitate the development and review of ne

Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 10 at 12:30pm ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage's website at investor.sagerx.c

Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

Agios Pharmaceuticals

Exelixis

Johnson & Johnson

Moderna

Novavax

Vertex Pharmaceuticals

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

Rush Enterprises

Virtus Investment Partners

When searching for value opportunities, investors could be interested in the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow (DCF) calculator.

These 3 Stocks Appear Underestimated by the Market

SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2021 Results - Earnings Call Transcript

Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD). What Happened: After talks with the FDA, the decision led the Company to believe it can seek approval without the data.

Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the second quarter ended June 30, 2021. “Sage has made incredible progress on our mission to become the leader in brain health in the first half of 2021, setting us up for multiple near-mid and long-t

Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, August 3, 2021 at 8:00 a.m. ET to announce second quarter 2021 financial results and discuss recent business updates. The webcast can be accessed on the investor page of Sage's website at investor.sagerx.co

Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Biogen

Novartis

Pfizer

uniQure

Roche Holding AG

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET. A live webcast of the presentation can be accessed on the investor page of Sage's website at

Sage Therapeutics to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at SVB Leerink's 3rd Annual CNS Forum on June 29th at 4:15pm ET. A live webcast of each presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of t

Sage Therapeutics to Participate in SVB Leerink's 3rd Annual CNS Forum

Sage has been struggling for some time to bring its flagship antidepressant to the market.

What Happened to Sage Therapeutics Stock?

The neuroscience-focused biotech company didn't give investors the result they wanted.

Here's Why Sage Therapeutics Tanked This Week

Innoviva

SIGA Technologies

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Sage Stock Declines on Late-Stage Depression Study Data

Long-awaited clinical trial results weren't as successful as hoped.

Here's Why Sage Therapeutics Stock Is Sliding Today

Sage Therapeutics Inc (NASDAQ: SAGE) said on Tuesday its candidate drug for depression that it developed in collaboration with Biogen Inc was found effective in alleviating the symptoms, as per the results of the late-stage trial. Despite meeting the goal of the study, Sage's stock tanked about 17% this morning.

Here's why Sage Therapeutics fell 18% on Tuesday morning

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 16.5% to trade at $60.85 at last check, following lackluster Phase 3 test results for the biotechnology company's depression drug, Zuranolone.

SAGE Plummets After Drug Trial Results

The stock price of SAGE Therapeutics Inc (NASDAQ: SAGE) fell by over 10% pre-market. This is why it happened.

SAGE Stock Price Falls Over 10% Pre-Market: Why It Happened

Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ: SAGE) revealed data from another Phase 3 evaluating zuranolone in patients with Major Depressive Disorder (MDD). Though the trial achieved the primary endpoint of statistically significant improvements in depressive symptoms compared with placebo at Day 15, some results have made investors react, thus sending SAGE shares down early Tuesday.

Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast this morning, June 15, 2021 at 8:00 a.m. ET to review topline results from the Phase 3 WATERFALL Study evaluating zuranolone for major depressive disorder. The webcast can be accessed on the investor page of Sage's website a

Sage Therapeutics to Host Conference Call

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Disorder (MDD). The 543-subject trial met its primary endpoint with zuranolone showing statistically significant improvement in depressive symptoms compared with placebo at Day 15.

Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score. LS means (SE) change from baseline in HAMD-17 total score at Day 15 for patien

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

News for SAGE Therapeutics Stock (SAGE)